{
  "docId": "019de076-4eee-72eb-9f75-bef42550a1c1",
  "docSlug": "3c2d586ebe2940705b3e5004470d76e3",
  "documentTitle": "Kymera | Investor Presentation Deck | 41 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 41,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 18,
  "notes": "The slide includes a disclaimer regarding the non-head-to-head nature of the comparison.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4eee-72eb-9f75-bef42550a1c1/17",
  "deckHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1",
  "deckJsonHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1.json",
  "deckAnchorHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Range from 7 different Phase 2 and Phase 3 trials; Range from 10 different Phase 2 and Phase 3 trials; Simpson EL, et al. NEJM 2016;375:2335-2348; Bieber T, et al. NEJM 2021;384:1101-1112; The Dupilumab clinical trial was conducted by other parties in a similar patient population with different enrollment criteria from Part 1C of our Phase 1 clinical trial evaluating KT-474. Results do not reflect a head-to-head trial and are shown for illustrative purposes only",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df71f1ea-a4e4-4203-90e3-a5da1326023c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "list",
      "text": "Encouraging initial EASI score reductions sustained after cessation of dosing; Peak pruritus reductions, and responder rates, significantly greater than placebo and SOC benchmarks; Investigator Global Assessment (IGA) scores improved in 2 of 7 patients and remained stable in the others",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8ac0c06-e84e-4d0f-8028-1602e590e586",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.9,
        "x": 0.05,
        "y": 0.4
      },
      "kind": "table",
      "text": "Comparison table of EASI, Peak Pruritus NRS, and Responder rates for KT-474 vs Placebo vs Dupilumab",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17cd1907-7d8a-4fa4-a833-631b94600cea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.1,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-474 Showed Meaningful Signs of Clinical Activity in AD, Comparing Favorably to Placebo Benchmarks and SOC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "148b5015-3ea9-484b-8c7a-3eb4c4d8fa39",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "bd030a31-963b-4b94-94d1-c5c16042893a",
      "evidence": "table/data: Comparison table of EASI, Peak Pruritus NRS, and Responder rates for KT-474 vs Placebo vs Dupilumab",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 10,
      "beatId": "76c0c72b-c82b-4ac5-891b-8e3593c8cc1e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck showcases encouraging clinical data for lead programs.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "481e5a5e-15c9-4f41-910c-aaa935cd7dad",
      "evidence": "The deck showcases encouraging clinical data for lead programs.",
      "position": 1,
      "objective": "What are the potential benefits of Kymera's platform?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}